CINECA IRIS Institutional Research Information System

CASSADER, Maurizio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.031
EU - Europa 11.842
AS - Asia 9.488
SA - Sud America 637
OC - Oceania 181
AF - Africa 146
Continente sconosciuto - Info sul continente non disponibili 25
Totale 40.350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.197
CN - Cina 5.412
IT - Italia 2.020
IE - Irlanda 1.507
SE - Svezia 1.453
SG - Singapore 1.119
FR - Francia 1.095
DE - Germania 1.032
UA - Ucraina 895
FI - Finlandia 722
KR - Corea 665
GB - Regno Unito 657
JP - Giappone 637
AT - Austria 476
CA - Canada 440
PL - Polonia 419
DK - Danimarca 377
MX - Messico 346
IN - India 324
VN - Vietnam 323
ES - Italia 285
BR - Brasile 277
RU - Federazione Russa 168
ID - Indonesia 165
AU - Australia 155
HK - Hong Kong 155
TW - Taiwan 153
TR - Turchia 147
BE - Belgio 129
NL - Olanda 111
GR - Grecia 107
PE - Perù 87
CO - Colombia 78
IR - Iran 70
CL - Cile 68
RO - Romania 66
TH - Thailandia 66
EC - Ecuador 56
AR - Argentina 53
CH - Svizzera 51
PT - Portogallo 51
PH - Filippine 43
CZ - Repubblica Ceca 42
EG - Egitto 40
MY - Malesia 39
SI - Slovenia 35
IL - Israele 30
SN - Senegal 29
NO - Norvegia 25
BY - Bielorussia 24
EU - Europa 24
HU - Ungheria 21
SA - Arabia Saudita 21
NZ - Nuova Zelanda 20
PK - Pakistan 16
ZA - Sudafrica 15
GT - Guatemala 14
IQ - Iraq 12
QA - Qatar 12
RS - Serbia 12
LU - Lussemburgo 11
VE - Venezuela 11
SK - Slovacchia (Repubblica Slovacca) 10
AE - Emirati Arabi Uniti 9
BG - Bulgaria 9
TN - Tunisia 9
CV - Capo Verde 8
MU - Mauritius 8
DZ - Algeria 7
JO - Giordania 7
LV - Lettonia 7
MM - Myanmar 7
MV - Maldive 7
BD - Bangladesh 6
GH - Ghana 6
HN - Honduras 6
HR - Croazia 6
KZ - Kazakistan 6
PA - Panama 6
UZ - Uzbekistan 6
AN - Antille olandesi 5
AZ - Azerbaigian 5
CR - Costa Rica 5
KE - Kenya 5
LB - Libano 5
SY - Repubblica araba siriana 5
BO - Bolivia 4
BA - Bosnia-Erzegovina 3
BF - Burkina Faso 3
CY - Cipro 3
ET - Etiopia 3
IS - Islanda 3
JM - Giamaica 3
LK - Sri Lanka 3
LT - Lituania 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
PG - Papua Nuova Guinea 3
SV - El Salvador 3
UY - Uruguay 3
Totale 40.313
Salva come PNG Salva come JPEG
Città #
Beijing 1.979
Chandler 1.851
Dublin 1.493
Ann Arbor 1.242
Singapore 833
Fairfield 828
Houston 784
Ashburn 718
Jacksonville 692
Villeurbanne 630
Wilmington 609
Princeton 579
Woodbridge 568
Redwood City 484
Medford 467
Vienna 438
Nyköping 437
Santa Clara 418
Dearborn 412
Shanghai 377
Columbus 376
Torino 372
Seattle 355
Warsaw 325
Cambridge 297
Pisa 296
Guangzhou 253
Dong Ket 223
Nanjing 218
Boston 216
Hangzhou 197
Boardman 175
Ottawa 160
Tokyo 149
Milan 134
Fremont 125
Wuhan 115
Jakarta 114
Chengdu 102
Taipei 101
Norwalk 95
Rome 93
Pune 90
New York 85
Toronto 83
Chongqing 81
Hefei 74
Helsinki 74
Shenyang 71
London 69
Jinan 66
Turin 66
Changsha 65
Tianjin 65
Munich 64
Brussels 63
Kunming 59
San Diego 58
Verona 58
Lima 54
Los Angeles 51
Phoenix 51
Washington 49
Zhengzhou 48
Falls Church 47
Istanbul 47
Menlo Park 46
Changchun 44
Santiago 44
San Mateo 43
Seoul 43
Xian 43
São Paulo 42
Central District 41
Frankfurt am Main 37
Düsseldorf 34
Fuzhou 34
Mexico City 34
Nanchang 34
Central 33
Madrid 32
Hong Kong 31
Silver Spring 30
West Jordan 30
Athens 29
Bogotá 29
Duncan 29
Paris 29
Chicago 28
Mexico 28
Mountain View 28
Saint-hubert 28
Berlin 27
Lachine 27
Barcelona 25
Xiamen 25
Saint Petersburg 24
Harbin 23
Mumbai 23
Riverton 22
Totale 22.967
Salva come PNG Salva come JPEG
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 2.466
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. 1.559
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 1.052
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis 900
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 824
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 768
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial 728
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. 681
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders 564
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. 506
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 429
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease 365
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease 309
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease 290
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution 279
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances 260
Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. 255
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis 233
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 233
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 227
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 215
Dietary flavonoid intake and cardiovascular risk: a population-based cohort study 215
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 200
Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. 196
Body fat and C-reactive protein levels in healthy non-obese men. 194
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 194
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials 194
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 191
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 190
Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. 184
In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control 177
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 177
The glucoregulatory and antilipolytic actions of insulin in abdominal obesity with normal or impaired glucose tolerance: an in vivo and in vitro study. 175
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 173
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 167
Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. 166
High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort. 164
Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 160
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 159
Serum glucose, insulin, C-peptide and plasma glucagon response to oral glucose after intravenous injection of different glucocorticoids at increasing doses in man 158
Body fat is the main predictor of fibrinogen levels in healthy non-obese men 155
Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man 154
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 153
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 152
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 150
Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. 149
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 149
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH 148
The rs553668 polymorphism of ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study 148
Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria 148
Relationships between human serum resistin, inflammatory markers and insulin resistance 145
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 144
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 144
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. 144
Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. 142
Lipoprotein(a) and insulin treatment in non insulin dependent diabetic patients 141
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 141
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) 141
Lipoprotein(a) and insulin treatment in NIDDM patients 140
Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. 138
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? 135
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 135
Feedback inhibition of insulin and glucagon secretion by insulin is altered in abdominal obesity with normal or impaired glucose tolerance. 135
Metabolic handling of an oral fat load in NAFLD patients. 135
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 134
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 134
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. 131
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 129
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 127
Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult Italian population-based cohort. 126
Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 126
Age related changes of glucagon binding and activity in isolated rat hepatocytes. 125
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 125
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 124
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 124
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 124
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? 123
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 120
Effetto della terapia steroidea sul controllo glicemico nel diabete insulino-trattato: confronto Deflazacort-Prednisone. 119
The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. 117
Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort 115
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 115
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII. 114
Non-alcoholic fatty liver disease from pathogenesis to management: an update. 114
Dietary interventions modify the gut microbiota during pregnancy in patients with gestational diabetes mellitus (GDM) 114
Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. 114
Nel soggetto normale la ferritemia correla con l’HOMA. 113
Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications 113
Adiponectin gene polymorphism modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH 112
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 111
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 110
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. 109
Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up 109
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 109
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 108
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 107
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? 106
Phytosterol-Enriched Yogurt Increases LDL Affinity and Reduces CD36 Expression in Polygenic Hypercholesterolemia 105
INCIDENCE AND SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE ASSOCIATED WITH IMPAIRED LIPID AND GLUCOSE METABOLISM ARE PREDICTED BY SREBF POLYMORPHISM. 105
Lipid modifiers and NASH: statins, ezetimibe, fibrates and other agents 103
Totale 24.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.678
article - articoli 0
book - libri 0
conference - conferenze 33.632
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.499 0 0 0 0 370 871 603 391 489 496 600 679
2020/20214.931 567 327 318 290 437 339 410 233 510 521 391 588
2021/20225.690 246 334 282 408 389 290 466 404 306 515 959 1.091
2022/20236.959 859 481 197 556 570 1.698 654 454 592 220 349 329
2023/20244.560 452 557 307 333 350 551 333 292 79 358 399 549
2024/20253.480 320 583 489 742 1.346 0 0 0 0 0 0 0
Totale 41.650